Richmond Pharmacology Establishes Expert Regulatory Advisory Board

Richmond Pharmacology, a leading clinical research organisation specialising in early-phase and innovative clinical trials, today announced the establishment of its Expert Regulatory Advisory Board (ERAB), bringing together former senior regulators and industry leaders to support clients navigating increasingly complex and evolving regulatory landscapes.

Chaired by Dr Lisa Campbell, Director of Regulatory Strategy at Richmond Pharmacology and former Senior Medical Assessor at the MHRA, and supported by Vice Chair James Rickard, Chief Scientific Officer of the Richmond Research Institute the ERAB brings deep experience across UK and EU regulatory authorities, pharmaceutical and biotechnology development, advanced therapies, and clinical trial oversight.

The Board has been formed to provide collective regulator-informed insight across the full drug development lifecycle, from first-in-human trials and innovative trial designs through to advanced therapies, inspection readiness, and global regulatory strategy. The Board will work with Richmond Pharmacology’s clinical and regulatory teams to ensure regulatory considerations are embedded early and pragmatically into trial delivery. By combining deep regulatory expertise with Richmond Pharmacology’s proven clinical trial delivery capabilities under one umbrella, sponsors can save significant time and reduce the risk of downstream regulatory challenges.

“Regulatory success depends on decisions made early and informed by real regulatory experience,” said Dr Lisa Campbell, Chair of the Regulatory Advisory Board. “This Board brings together former MHRA and EMA leaders, inspectors, and senior regulatory strategists to provide sponsors with access to collective regulatory insight that is practical, proportionate, and aligned with the realities of modern clinical development.”

‍

The Expert Regulatory Advisory Board encompasses expertise spanning:

• Scientific advice and agency engagement

• First-in-human and complex trial design

• Nonclinical and clinical regulatory strategy

• ATMP and emerging modality development

• GCP, inspection readiness, and data governance

• Regulatory oversight across the UK, EU, and international frameworks

‍

The establishment of the ERAB reflects Richmond Pharmacology’s continued investment in regulatory excellence and its commitment to integrating regulatory strategy seamlessly with clinical trial delivery.

“Our clients are developing complex, innovative programmes that benefit from early, informed regulatory engagement,” said Dr Ulrike Lorch, Chief Medical Director and Principal Investigator at Richmond. “By embedding this depth of regulatory expertise within our organisation, we can support sponsors in progressing efficiently through development, true to our mission ‘Faster Answers’.”

The ERAB will support Richmond Pharmacology’s regulatory strategy services, scientific advice preparation, and client-facing regulatory initiatives across the UK, Europe, and internationally.

‍

Read more here: Pharmiweb